<code id='F35BDDB638'></code><style id='F35BDDB638'></style>
    • <acronym id='F35BDDB638'></acronym>
      <center id='F35BDDB638'><center id='F35BDDB638'><tfoot id='F35BDDB638'></tfoot></center><abbr id='F35BDDB638'><dir id='F35BDDB638'><tfoot id='F35BDDB638'></tfoot><noframes id='F35BDDB638'>

    • <optgroup id='F35BDDB638'><strike id='F35BDDB638'><sup id='F35BDDB638'></sup></strike><code id='F35BDDB638'></code></optgroup>
        1. <b id='F35BDDB638'><label id='F35BDDB638'><select id='F35BDDB638'><dt id='F35BDDB638'><span id='F35BDDB638'></span></dt></select></label></b><u id='F35BDDB638'></u>
          <i id='F35BDDB638'><strike id='F35BDDB638'><tt id='F35BDDB638'><pre id='F35BDDB638'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:483
          Cigna Healthcare's logo on a phone
          Adobe

          CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon.

          A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.

          advertisement

          The case is a prominent example of why the health care industry, and corporate America writ large, does not want noncompetes to go away. In April, the Federal Trade Commission approved a nationwide ban on most such agreements, which prevent workers from moving to other jobs, but companies and corporate lobbying groups have already sued to squash the ban.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          STAT Wunderkinds: Ruey Hu's digital tools for parsing research
          STAT Wunderkinds: Ruey Hu's digital tools for parsing research

          HugraduatingfromJohnsHopkinsandbeinginductedintotheDeltaOmegaPublicHealthHonorSocietyin2017.Courtesy

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          ASCO eve: Let’s set the table for this year's meeting

          ThisistheonlineeditionofAdam’sBiotechScorecard,asubscriber-onlynewsletter.STAT+subscriberscansignuph